The specialty pharmaceutical company said Gulfo’s addition enhances the board’s commercial and business development expertise.
Gulfo is currently chief of commercial development at Roivant Sciences Ltd and was chief strategy officer of Mylan NV (NASDAQ:MYL) before that. She spent 14 years in various senior roles at Pfizer Inc (NYSE:PFE) and spent nine years AstraZeneca PLC (NYSE:AZN), where she ran the Cardiovascular and Diabetes Business Unit.
Among her accomplishments, Gulfo helped launch Lipitor, which became the world's best-selling medicine with peak revenues of US$13.7 billion globally. She also oversaw the launch and growth of Crestor, which achieved peak sales of US$6 billion. She also ran teams that grew Toprol-XL to US$2 billion from US$200 million.
“We are thrilled to add Adele to our board of directors,” said Ken d’Entremont, CEO of Montreal-based Medexus, in a statement. “She brings deep global experience in both business development and commercialization of multi-billion-dollar products. Her knowledge and experience will be invaluable in helping guide the growth of our existing portfolio, as well as in identifying new products that can be added to our product pipeline as we continue on our rapid growth trajectory across North America.”
As a scientist, Gulfo holds eight US patents and serves as an advisory board member of Partners Healthcare (founded by Brigham and Women’s Hospital and Massachusetts General Hospital) and Springboard Life Sciences.
Contact Paul Curcio at [email protected]
Follow him on Twitter @GoCurcioGo